Antiarrhythmic versus both Control and Antiarrhythmic: study Included in the Systematic review
DISEASE INTERVENTION COMPARISON RESULTS
G Ital Cardiol. 1996 Apr;26(4):379-90 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Curr Ther Res Clin Exp. 1995;56(11):1154-1168 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Cardiology Review 2002;19(9):18-21 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Munchener Medizinische Wochenschrift. 1996;138 (12):39-46 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 2001 Sep 15;88(6):640-5 Randomized Controlled Trial
IN StudyID: Bellandi 2001, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
G Ital Cardiol. 1995 Jan;25(1):51-68 Randomized Controlled Trial
IN StudyID: Carunchio 1995, atrial fibrillation, paroxysmal The Use of
flecainide, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adeverse effects - at 12 months
Drugs. 1999 Dec;58(6):1043-59 Review (Narrative)
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Circulation. 1998 Oct 27;98(17):3326 Suppl. I-633 Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
J Am Coll Cardiol. 2000 Feb;35(2 Suppl. A):154A-155A Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To mortality at 1 year
Circulation. 1998 Oct 27;98(17):66 Suppl. 13-14 Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Accessed 2010 August 10 at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-931_Tikosyn.cfm Randomized Controlled Trial
IN StudyID: EMERALD 1998, atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To reduce, at 1 year, AF recurrence. But they did not modified mortality and both increased adverse events and pro-arrhythmia
N Engl J Med. 2007 Sep 6;357(10):987-99 Randomized Controlled Trial, Multicenter Study
IN StudyID: EURIDIS ADONIS 2004, atrial fibrillation The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce at 1 year recurrence of AF (% of recurrences ?). Effect on mortality, stroke, heart failure ?
Chest. 2004 Feb;125(2):377-83 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmPro 2004, atrial fibrillation The Use of
amiodarone, propafenone
As Treatment, Chronic
Is good Than
0
To AF recurrence, adverse effects - at 10 months
Am J Cardiol. 1998 Apr 15;81(8):995-8 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000 (subordinated publication DVD), atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol
To AF recurrence, adverse effects - at 12 months
Pacing Clin Electrophysiol. 2000 Nov;23(11 Pt 2):1883-7 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000 (subordinated publication), atrial fibrillation The Use of
amiodarone, propafenone
As Treatment, Chronic
Is better Than
sotalol
To AF recurrence, adverse effects - at 6 to 16 months
Heart 2000 Sep;84(3):251-7 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000, atrial fibrillation The Use of
amiodarone, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 to 16 months
Am J Cardiol. 2004 Dec 15;94(12):1563-6 Randomized Controlled Trial
IN StudyID: Kochiadakis-ProSot 2004, atrial fibrillation The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, pro-arrhythmia, AF recurrence, adverse effects - at 18 to 25 months
S Afr Med J 1984 Mar 10;65(10):367-9 Randomized Controlled Trial
IN StudyID: Lloyd 1984, atrial fibrillation The Use of
quinidine, disopyramide
As Treatment, Chronic
Is equal Than
placebo
To mortality, stroke, AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Z Kardiol 1999 Mar;88(3):195-207 Randomized Controlled Trial
IN StudyID: PAFAC (subordinated publication), atrial fibrillation, persistent The Use of
quinidine, sotalol
As Treatment, Chronic
Is - Than
placebo
To mortality, AF recurrence - at 12 months
Eur Heart J. 2004 Aug;25(16):1385-94 Randomized Controlled Trial
IN StudyID: PAFAC, atrial fibrillation, persistent The Use of
quinidine, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, adverse effects, pro-arrhythmia, AF recurrence - at 12 months
Am J Cardiol. 2003 Aug 15;92(4):468-72 Randomized Controlled Trial
IN StudyID: Safe-T 2005 (subordinated publication), atrial fibrillation The Use of
amiodarone, sotalol
As Treatment, Chronic
Is - Than
placebo
To AF recurrence, a number of parameters as secondary end points - at 12 to 54 months
N Engl J Med. 2005 May 5;352(18):1861-72 Randomized Controlled Trial
IN StudyID: Safe-T 2005, atrial fibrillation, persistent The Use of
amiodarone, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, stroke, proarrhythmia, AF recurrence - at 12 months
Z Kardiol (Zeitschrift fur Kardiologie) 1999 Mar;88(3):185-94 Randomized Controlled Trial
IN StudyID: SOPAT (subordinated publication), atrial fibrillation, paroxysmal The Use of
quinidine, sotalol
As Treatment, Chronic
Is - Than
placebo
To at 12 months: AF recurrence, adverse effects, pro-arrhythmia, mortality
Eur Heart J. 2004 Aug;25(16):1395-404 Randomized Controlled Trial
IN StudyID: SOPAT, atrial fibrillation, paroxysmal The Use of
quinidine, sotalol
As Treatment, Chronic
Is better Than
placebo
To at 12 months: AF recurrence, adverse effects, pro-arrhythmia, mortality
Dtsch Med Wochenschr. 1988 Dec 2;113(48):1867-71 Randomized Controlled Trial
IN StudyID: Steinbeck 1988, atrial fibrillation, paroxysmal The Use of
flecainide, quinidine
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse affects - at 11 months